NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment

University of Toronto70 enrolled

Overview

The newly designed contraceptive ring, Nuvaring has a lower total steroid dose, and medications are delivered locally. It has been proven to be as safe and effective as the combined OCP in ovarian suppression and preventing ovulation with fewer side effects due to minimal systemic absorption. Following a single vaginal insertion, steroid concentrations remain stable for up to 4 weeks. It is hypothesized that Nuvaring may, therefore lead to better compliance, tolerability and acceptance by patients requiring ovarian suppression prior to COH for IVF.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Infertility In-vitro Fertilization

Interventions

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 38 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients less than 38 years of age. * Healthy women starting their first IVF/ICSI cycle. * No contraindication to Combined Oral Contraceptive (COC) use. Appendix 1 * Consent to randomization. Exclusion Criteria: * Any contraindication to COC use. * Hypersensitivity to Nuva ring or any of its components. * Language barrier to consent.

Outcomes

Primary Outcomes

Incidence of Side Effects of Oral Contraceptives Such as Abnormal Bleeding, Headache, Breast Discomfort, Bloating and Mood Swings (See Description)

abnormal bleeding, intermittent bleeding, headache, breast discomfort, bloating, mood swings, nausea, vaginal discharge, vomitting, weight gain

Time frame: patients were followed for the duration of an in-vitro fertilization cycle- 2 months